Vasospasm after aneurysmal subarachnoid hemorrhage: Recent advances in endovascular management

Current Opinion in Critical Care

Volumn 16, Issue 2, 2010, Pages 110-116

  Pierot, Laurent ^a   Aggour, Mohamed ^a   Moret, Jacques ^b  

^a HÔPITAL MAISON BLANCHE   (France)

^b FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

Late complications; Subarachnoid hemorrhage; Vasospasm

Indexed keywords

FASUDIL; MAGNESIUM SULFATE; MILRINONE; NICARDIPINE; NIMODIPINE; NORADRENALIN; PAPAVERINE; VASOACTIVE AGENT; VERAPAMIL;

ABSENCE OF SIDE EFFECTS; ACUTE HEART FAILURE; BRAIN ANGIOGRAPHY; BRAIN ARTERY ANEURYSM; BRAIN DAMAGE; BRAIN INFARCTION; BRAIN INJURY; BRAIN OXYGEN TENSION; BRAIN VASOSPASM; CLINICAL DECISION MAKING; COMBINATION CHEMOTHERAPY; CONSCIOUSNESS DISORDER; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INTRACRANIAL HYPERTENSION; INVASIVE PROCEDURE; KIDNEY DISEASE; MEAN ARTERIAL PRESSURE; MENTAL DEFICIENCY; MENTAL DETERIORATION; MONOTHERAPY; NEUROPROTECTION; OCCLUSIVE CEREBROVASCULAR DISEASE; PATIENT CARE; PATIENT SAFETY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; TACHYCARDIA; THERAPY EFFECT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNILATERAL BLINDNESS; VASOSPASM;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANGIOPLASTY, BALLOON; CRITICAL CARE; ENDOVASCULAR PROCEDURES; HUMANS; INTENSIVE CARE UNITS; MILRINONE; NICARDIPINE; PAPAVERINE; RISK FACTORS; SUBARACHNOID HEMORRHAGE; VASODILATOR AGENTS; VASOSPASM, INTRACRANIAL; VERAPAMIL;

EID: 77952271882     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e3283372ef2     Document Type: Review

References (71)

1. Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol 2007;3:256-263. (Pubitemid 46745473)
2. Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL. Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke 2007;38:2315-2321. (Pubitemid 47457575)
3. Zwienenberg-Lee M, Hartman J, Rudisill N, et al. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke 2008;39:1759-1765. This study illustrates the nonefficiency of prophylactic TBA in CVS on patients' outcome.
4. Kassell NF. The role of vasospasmin overall outcome from aneurysmal subarachnoid hemorrhage. In: Findlay JM, editor. Cerebral vasospasm. Amsterdam: Elsevier; 1993. pp. 27-28.
5. Macdonald RL, Weir B. Cerebral vasospasm: prevention and treatment. In: Batjer HH, Caplan LR, Friberg L, et al., editors. Cerebrovascular disease. Philadelphia: Lippincott Raven; 1997. pp. 1111-1121.
6. Janardhan V, Biondi A, Riina HA, et al. Vasospasm in aneurysmal subarachnoid hemorrhage: diagnosis, prevention, and management. Neuroimaging Clin N Am 2006;16:483-496. (Pubitemid 44279990)
7. Smith RR, Clower BR, Grotendorst GM, et al. Arterial wall changes in early human vasospasm. Neurosurgery 1985;16:171-176.
8. Macdonald RL, Weir BK. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 1991;22:971-982.
9. Suzuki H, Muramatsu M, Kojima T, Taki W. Intracranial heme metabolism and cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 2003;34:2796-2800. (Pubitemid 37517744)
10. Fuwa I, Mayberg M, Gadjusek C, et al. Enhanced secretion of endothelin by endothelial cells in response to hemoglobin. Neurol Medico-chirurgica 1993;33:739-743. (Pubitemid 24000328)
11. Rubanyi GM. Endothelium-derived relaxing and contracting factors. J Cell Biochem 1991;46:27-36.
12. Macdonald RL, Rosengart A, Huo D, Karrison T. Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage. J Neurosurg 2003;99:644-652. (Pubitemid 37159040)
13. Mocco J, Ransom ER, Komotar RJ, et al. Racial differences in cerebral vasospasm: a systematic review of the literature. Neurosurgery 2006;58:305-314. (Pubitemid 43212788)
14. Adams HP Jr, Kassell NF, Torner JC, Haley EC Jr. Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study. Neurology 1987;37:1586-1591.
15. Hijdra A, van Gijn J, Nagelkerke NJ, et al. Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage. Stroke 1988;19:1250-1256.
16. Roos Y, Rinkel G, Vermeulen M, et al. Antifibrinolytic therapy for aneurysmal subarachnoid hemorrhage: a major update of a Cochrane review. Stroke 2003;34:2308-2309. (Pubitemid 37099855)
17. Fergusen S, Macdonald RL. Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2007;60:658-667. (Pubitemid 46581089)
18. Frontera JA, Claassen J, Schmidt JM, et al. Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified fisher scale. Neurosurgery 2006;59:21-27. (Pubitemid 44024334)
19. Rosen DS, Amidei C, Tolentino J, et al. Subarachnoid clot volume correlates with age, neurological grade, and blood pressure. Neurosurgery 2007;60:259-267. (Pubitemid 46253786)
20. Weyer GW, Nolan CP, Macdonald RL. Evidence-based cerebral vasospasm management. Neurosurg Focus 2006; 21: E8.
21. Komotar RJ, Zacharia BE, Valhora R, et al. Advances in vasospasm treatment and prevention. J Neurol Sci 2007;261:134-142. (Pubitemid 47313506)
22. Zwienenberg-Lee M, Hartman J, Rudisill N, Muizelaar JP. Endovascular management of cerebral vasospasm. Neurosurgery 2006; 59: S139-147. (Pubitemid 44622718)
23. Weiss N, Sanchez-Pena P, Roche S, et al. Prognosis value of plasma S100B protein levels after subarachnoid hemorrhage. Anesthesiology 2006;104:658-666.
24. Elsayed AA, Moran CJ, Cross DT III, et al. Effect of intraarterial papaverine and/or angioplasty on the cerebral veins in patients with vasospasm after subarachnoid hemorrhage due to ruptured intracranial aneurysms. Neurosurg Focus 2006; 21: E16.
25. Hoh BL, Ogilvy CS. Endovascular treatment of cerebral vasospasm: transluminal balloon angioplasty, intra-arterial papaverine, and intra-arterial nicardipine. Neurosurg Clin N Am 2005;16:501-516.
26. Kirmani JF, Alkawi A, Ahmed S, et al. Endovascular treatment of subarachnoid hemorrhage. Neurol Res 2005; 27 (1 Suppl) : S103-S107. (Pubitemid 41510939)
27. Liu JK, Couldwell WT. Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. Neurocrit Care 2005;2:124-132.
28. Mindea SA, Yang BP, Bendok BR, et al. Endovascular treatment strategies for cerebral vasospasm. Neurosurg Focus 2006; 21: E13.
29. Oskouian RJ Jr, Martin NA, Lee JH, et al. Multimodal quantitation of the effects of endovascular therapy for vasospasm on cerebral blood flow, transcranial doppler ultrasonographic velocities, and cerebral artery diameters. Neurosurgery 2002;51:30-43.
30. Sawada M, Hashimoto N, Tsukahara T, et al. Effectiveness of intra-arterially infused papaverine solutions of various concentrations for the treatment of cerebral vasospasm. Acta Neurochir (Wien) 1997;139:706-711. (Pubitemid 27354716)
31. Elliott JP, Newell DW, Lam DJ, et al. Comparison of balloon angioplasty and papaverine infusion for the treatment of vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 1998;88:277-284.
32. Firlik AD, Kaufmann AM, Jungreis CA, Yonas H. Effect of transluminal angioplasty on cerebral blood flow in the management of symptomatic vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg 1997;86:830-839. (Pubitemid 27187686)
33. Vajkoczy P, Horn P, Bauhuf C, et al. Effect of intra-arterial papaverine on regional cerebral blood flow in hemodynamically relevant cerebral vasospasm. Stroke 2001;32:498-505. (Pubitemid 32155242)
34. Andaluz N, Tomsick TA, Tew JM Jr, et al. Indications for endovascular therapy for refractory vasospasm after aneurysmal subarachnoid hemorrhage: experience at the University of Cincinnati. Surg Neurol 2002;58:131-138. (Pubitemid 35365913)
35. Cross DT III, Moran CJ, Angtuaco EE, et al. Intracranial pressure monitoring during intraarterial papaverine infusion for cerebral vasospasm. AJNR Am J Neuroradiol 1998;19:1319-1323. (Pubitemid 30418681)
36. McAuliffe W, Townsend M, Eskridge JM, et al. Intracranial pressure changes induced during papaverine infusion for treatment of vasospasm. J Neurosurg 1995;83:430-434.
37. Smith WS, Dowd CF, Johnston SC, et al. Neurotoxicity of intra-arterial papaverine preserved with chlorobutanol used for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 2004;35:2518-2522.
38. Qureshi AI, Sung GY, Razumovsky AY, et al. Early identification of patients at riskfor symptomatic vasospasm after aneurysmal subarachnoid hemorrhage. Crit Care Med 2000;28:984-990.
39. Stiefel MF, Spiotta AM, Udoetuk JD, et al. Intra-arterial papaverine used to treat cerebral vasospasm reduces brain oxygen. Neurocrit Care 2006;4:113-118.
40. Biondi A, Ricciardi GK, Puybasset L, et al. Intra-arterial nimodipine for the treatment of symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage: preliminary results. AJNR Am J Neuroradiol 2004;25:1067-1076. (Pubitemid 38765893)
41. Feigin VL, Rinkel GJ, Algra A, et al. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology 1998;50:876-883. (Pubitemid 28212809)
42. Badjatia N, Topcuoglu MA, Pryor JC, et al. Preliminary experience with intraarterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol 2004;25:819-826. (Pubitemid 38657670)
43. Hanggi D, Turowski B, Beseoglu K, et al. Intra-arterial nimodipine for severe cerebral vasospasm after aneurysmal subarachnoid hemorrhage: influence on clinical course and cerebral perfusion. AJNR Am J Neuroradiol 2008;29:1053-1060. (Pubitemid 351954866)
44. Fraticelli AT, Cholley BP, Saint Maurice JP, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 2008;39:893-898. This study shows the outcome of the combined use of intraarterial and i.v. milrinone in treatment of CVS. Technical points and management are very well illustrated. (Pubitemid 351619546)
45. Oates JA, Brown NJ. Antihypertensive agents and the drug therapy of hypertension. In: Goodman LS, Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. pp. 871-900.
46. Linfante I, Delgado-Mederos R, Andreone V, et al. Angiographic and hemodynamic effect of high concentration of intra-arterial nicardipine in cerebral vasospasm. Neurosurgery 2008;63:1080-1086; discussion 1086-1087.
47. Nogueira RG, Lev MH, Roccatagliata L, et al. Intra-arterial nicardipine infusion improves CT perfusion-measured cerebral blood flow in patients with subarachnoid hemorrhage-induced vasospasm. AJNR Am J Neuroradiol 2009;30:160-164. Another parameter studied to prove the efficacy of nicardipine and its effect on the brain perfusion.
48. Van Den Bergh WM, Algra A, van der Sprenkel JW, et al. Hypomagnesemia after aneurysmal subarachnoid hemorrhage. Neurosurgery 2003;52:276-281; discussion 281-282. (Pubitemid 36159414)
49. Macdonald RL, Curry DJ, Aihara Y, et al. Magnesium and experimental vasospasm. J Neurosurg 2004;100:106-110. (Pubitemid 38017822)
50. Veyna RS, Seyfried D, Burke DG, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg 2002;96:510-514. (Pubitemid 34230205)
51. Van den Bergh WM, Algra A, van Kooten F, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke 2005;36:1011-1015. (Pubitemid 40629294)
52. Prevedello DM, Cordeiro JG, de Morais AL, et al. Magnesium sulfate: role as possible attenuating factor in vasospasm morbidity. Surg Neurol 2006; 65 (Suppl 1) : S1-S20.
53. Shah QA, Memon MZ, Suri MF, et al. Super-selective intra-arterial magnesium sulfate in combination with nicardipine for the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. Neurocrit Care 2009;11:190-198. This study points to the relation between hypomagnesemia and CVS. Efficacy of magnesium sulfate on CVS is contradictory in the literature but its use is well tolerated.
54. Feng L, Fitzsimmons BF, Young WL, et al. Intraarterially administered verapamil as adjunct therapy for cerebral vasospasm: safety and 2-year experience. AJNR Am J Neuroradiol 2002;23:1284-1290. (Pubitemid 35033874)
55. Keuskamp J, Murali R, Chao KH. High-dose intraarterial verapamil in the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg 2008;108:458-463. (Pubitemid 351357976)
56. Tachibana E, Harada T, Shibuya M, et al. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien) 1999;141:13-19. (Pubitemid 29062727)
57. Tanaka K, Minami H, Kota M, et al. Treatment of cerebral vasospasm with intraarterial fasudil hydrochloride. Neurosurgery 2005;56:214-223. (Pubitemid 40204936)
58. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Description of a new technical and a preliminary report of its application. Circulation 1964;30:654-670.
59. Zubkov YN, Nikiforov BM, Shustin VA. Balloon catheter technique for dilatation of constricted cerebral arteries after aneurysmal SAH. Acta Neurochir (Wien) 1984;70:65-79.
60. Megyesi JF, Findlay JM, Vollrath B, et al. In vivo angioplasty prevents the development of vasospasm in canine carotid arteries. Pharmacological and morphological analyses. Stroke 1997;28:1216-1224.
61. Jestaedt L, Pham M, Bartsch AJ, et al. The impact of balloon angioplasty on the evolution of vasospasm-related infarction after aneurysmal subarachnoid hemorrhage. Neurosurgery 2008;62:610-617. (Pubitemid 351572757)
62. Murai Y, Kominami S, Kobayashi S, et al. The long-term effects of transluminal balloon angioplasty for vasospasms after subarachnoid hemorrhage: analyses of cerebral blood flow and reactivity. Surg Neurol 2005;64:122-127. (Pubitemid 41044132)
63. Fujii Y, Takahashi A, Yoshimoto T. Effect of balloon angioplasty on high grade symptomatic vasospasm after subarachnoid hemorrhage. Neurosurg Rev 1995;18:7-13.
64. Newell DW, Eskridge J, Mayberg M, et al. Endovascular treatment ofintracranial aneurysms and cerebral vasospasm. Clin Neurosurg 1992;39:348-360.
65. Terry A, Zipfel G, Milner E, et al. Safety and technical efficacy of over-the-wire balloons for the treatment of subarachnoid hemorrhage-induced cerebral vasospasm. Neurosurg Focus 2006; 21: E14.
66. Merchant A, Drazin D, Dalfino J, et al. Delayed stenosis as a consequence of angioplasty for subarachnoid hemorrhage-induced vasospasm. Neurosurg Focus 2009; 26: E23.
67. Sedat J, Chau Y, Popolo M, et al. Restenosis after balloon angioplasty for cerebral vasospasm. Cardiovasc Intervent Radiol 2009;32:337-340.
68. Yamamoto Y, Smith RR, Bernanke DH. Mechanism of action of balloon angioplasty in cerebral vasospasm. Neurosurgery 1992;30:1-6.
69. Laurindo FRM, Daluz PL, Uint L, et al. Evidence for superoxide radicaldependent coronary vasospasm after angioplasty in intact dogs. Circulation 1991;83:1705-1715.
70. Eskridge JM, McAuliffe W, Song JK, et al. Balloon angioplasty for the treatment of vasospasm: results of first 50 cases. Neurosurgery 1998;42:510-517. (Pubitemid 28128736)
71. Rosenwasser RH, Armonda RA, Thomas JE, et al. Therapeutic modalities for the management of cerebral vasospasm: timing of endovascular options. Neurosurgery 1999;44:975-980.